Treating cancer today is a battle of annihilation where we've completely ignored the collateral chronology. When we hit a patient with genotoxic stress to stop a tumor, we aren't just killing cells; we're pushing the whole somatic population into accelerated deep quiescence. Survivors might hit that five-year milestone, but they've often aged fifteen biological years in just six months.

If we want to reach a world of indefinite healthspan, our current oncology toolkit is a catastrophic loan with a predatory interest rate. We're liquidating the future to pay for the present. By inducing systemic DNA damage and the macromolecular dilution of repair factors, we're creating a cohort of 'biological ghosts'—people who survived the malignancy but whose cellular machinery is too exhausted to ever participate in a rejuvenated future.

Does a life without a fixed end-date require a different kind of medical bravery? If you knew you could realistically live for three centuries, would you accept a treatment that saves you today but caps your total biological horizon at eighty? Our ethics are built on the scarcity of time. We prioritize 'not dying' because we assume death is the only ultimate failure.

But in the context of longevity, the real failure is landscape flattening. It’s the state where the cell survives but loses the energetic capacity to differentiate, repair, or respond to its environment. Oncology’s biggest wins are currently longevity's most expensive losses. We're curing the 'what' while destroying the 'why.'

We need to fund senolytic-integrated oncology and protocols that prioritize the kinetic sovereignty of healthy tissue during treatment. This means bridging the gap between cancer research and aging biology. They shouldn't be separate silos; they're a singular problem of informational integrity. If we don't fix the sequence, we aren't extending life. We're just stretching the duration of the wreck.